A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Phase 1 Completed 103 enrolled Merck Sharp & Dohme LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.

Timeline

Start: 2005-04
Primary completion: 2011-08
Completion: 2011-08

Publications

Results Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2307-13. doi: 10.1200/JCO.2011.39.1540. Epub 2012 Apr 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-0752	Small molecule	300 mg	Oral
Subject	MK-0752	Small molecule	350 mg	Oral
Subject	MK-0752	Small molecule	450 mg	Oral
Subject	MK-0752	Small molecule	600 mg	Oral
Subject	MK-0752	Small molecule	800 mg	Oral
Subject	MK-0752	Small molecule	900 mg	Oral
Subject	MK-0752	Small molecule	1000 mg	Oral
Subject	MK-0752	Small molecule	1200 mg	Oral
Subject	MK-0752	Small molecule	1400 mg	Oral
Subject	MK-0752	Small molecule	1500 mg	Oral
Subject	MK-0752	Small molecule	1800 mg	Oral
Subject	MK-0752	Small molecule	2400 mg	Oral
Subject	MK-0752	Small molecule	3200 mg	Oral
Subject	MK-0752	Small molecule	4200 mg	Oral

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Summary

Timeline

Publications

Drugs

Indications